Cross-source identity
National Provider Identifier 1508190133 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1508190133 | Registry identity — dermatologist, taxonomy 207NP0225X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1508190133 | 10 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| Fonteum entity graph | entity 2711c95c… | Canonical resolved node · 4 identifier(s) · 0 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $310 | 10 |
| Manufacturer | Amount | Records |
|---|---|---|
| Pfizer Inc. | $103 | 1 |
| Leo Pharma Inc. | $50 | 2 |
| Arcutis Biotherapeutics, Inc. | $42 |
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| 2 |
| Pierre Fabre Pharmaceuticals, Inc. | $42 | 1 |
| Incyte Corporation | $40 | 2 |